Monoethanolamine

Monoethanolamine

SCHEMBL1330822

[2H]C([2H])(N)C([2H])([2H])O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MPL

The experimentally established mechanism targets of Monoethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Monoethanolamine SCHEMBL12208272 0.80
Ethylene Glycol SCHEMBL2307225 0.72
Ethylenediamine SCHEMBL1331150 0.72
SCHEMBL13750804 0.70
Monoethanolamine SCHEMBL13534425 0.70
Ethylenediamine SCHEMBL1330814 0.67
SCHEMBL4957834 0.65
SCHEMBL19053 0.65
1,3-Propanediol SCHEMBL3133442 0.63
1,4-Butanediol SCHEMBL2537863 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739652-A1 LIPIDS AND COMPOSITIONS THEREOF Kernal Biologics, Inc. (US) 2026-05-13 EP disclosed
WO-2025010290-A1 LIPIDS AND COMPOSITIONS THEREOF KERNAL BIOLOGICS, INC. (US) 2025-01-09 WO disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 EP disclosed
US-20230106002-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. 2023-04-06 US disclosed
CN-110016020-B Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof 赛克里翁治疗有限公司 2022-07-26 CN disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 EP disclosed
WO-2022072634-A1 BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-04-07 WO disclosed
US-11267804-B2 (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity JANSSEN PHARMACEUTICA NV (BE) 2022-03-08 US disclosed
EP-3660013-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2022-01-19 EP disclosed
US-11207323-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-12-28 US disclosed
US-20120129849-A1 DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20110282587-A1 COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY EMORY UNIVERSITY (US) 2011-11-17 US disclosed
WO-2011059610-A1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-05-19 WO disclosed
US-7425451-B2 Triazine derivatives as universal peptide isotope tag reagents (U-PIT) AGILENT TECHNOLOGIES, INC. (US) 2008-09-16 US disclosed
US-20070031973-A1 Triazine derivatives as universal peptide isotope tag reagents (U-PIT) ROBOTTI KARLA M 2007-02-08 US disclosed
US-7109040-B2 Modular isotope coding approach to proteomic analysis AGILENT TECHNOLOGIES, INC. (US) 2006-09-19 US disclosed
US-20050100956-A1 Modular isotope coding approach to proteomic analysis AGILENT TECHNOLOGIES, INC. 2005-05-12 US disclosed
US-20040115821-A1 Triazine derivatives as universal peptide isotope tag reagents (U-PIT) AGILENT TECHNOLOGIES, INC. 2004-06-17 US disclosed
EP-1429147-A1 Universal reagent for isotopically tagging peptides Agilent Technologies, Inc. (US) 2004-06-16 EP disclosed
EP-1429146-A1 Proteomic analysis Agilent Technologies, Inc. (US) 2004-06-16 EP disclosed